Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a rapid ex vivo tumor platform for drug response prediction in lung cancer.

NPJ precision oncology·2026
Same author

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026
Same author

A new surface to target: Glypican-1-directed ADCs in lung squamous cell carcinoma.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology.

NPJ precision oncology·2026
Same author

Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancer.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.

European journal of cancer (Oxford, England : 1990)·2026

Related Experiment Video

Updated: Apr 6, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Targeting MET in EGFR-Mutated NSCLC.

Stephanie P L Saw1, Molly S C Li2, Sehhoon Park3

  • 1Division of Medical Oncology, National Cancer Centre Singapore, Singapore.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|April 5, 2026
PubMed
Summary

MET alterations cause resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated non-small cell lung cancer (NSCLC). Targeting both EGFR and MET offers a promising strategy, but challenges in diagnosis and treatment sequencing remain.

Keywords:
EGFRMETNSCLCResistance

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Related Experiment Videos

Last Updated: Apr 6, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • MET alterations (amplification, overexpression) are key resistance mechanisms to EGFR TKIs in EGFR-mutated NSCLC.
  • MET dysregulation activates oncogenic signaling, justifying dual EGFR and MET inhibition.

Purpose of the Study:

  • Review strategies for targeting MET alterations in EGFR-mutated NSCLC.
  • Emphasize clinical relevance of differentiating MET amplification from c-MET overexpression.
  • Discuss diagnostic and therapeutic approaches.

Main Methods:

  • Review of current literature on MET-targeted therapies in EGFR-mutated NSCLC.
  • Analysis of diagnostic strategies: FISH, NGS, IHC, ctDNA assays.
  • Evaluation of clinical data for TKIs, ADCs, and bispecific antibodies.

Main Results:

  • Dual inhibition of EGFR and MET is a rational approach.
  • Various diagnostic methods exist, each with limitations (e.g., ctDNA assays).
  • Clinical data support EGFR- and MET-directed therapies across different classes.

Conclusions:

  • Distinguishing MET amplification from c-MET overexpression is clinically relevant.
  • Unresolved challenges include biomarker standardization, optimal timing, and sequencing of therapies.
  • Improved biomarker precision and optimized strategies are crucial for maximizing treatment benefits.